Botulinum toxin potentiates cancer radiotherapy and chemotherapy

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1276-1283

  Ansiaux, Réginald ^a   Baudelet, Christine ^a   Cron, Greg O ^a   Segers, Jérôme ^a   Dessy, Chantal ^a   Martinive, Philippe ^a   De Wever, Julie ^a   Verrax, Julien ^a   Wauthier, Valérie ^a   Beghein, Nelson ^a   Grégoire, Vincent ^a   Calderon, Pedro Bue ^a   Feron, Olivier ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CASPASE 3; CYCLOPHOSPHAMIDE; NEUROTRANSMITTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLONOGENESIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITOMETRY; DRUG POTENTIATION; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; FIBROSARCOMA; IMMUNOBLOTTING; LIVER CELL CARCINOMA; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIMETRY; OXYGENATION; PERFUSION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIATION DOSE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BOTULINUM TOXIN TYPE A; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; NEUROMUSCULAR AGENTS; OXYGEN; PERFUSION; SAPHENOUS VEIN; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 33644783745     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1222     Document Type: Article

References (31)

1. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 2004;25:536-42.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
4. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005;41: 1109-16.
5. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.
6. Padera TP, Stoll BR, Tooredman JB, Capen D, Di Tomaso E, Jain RK. Cancer cells compress intratumor vessels. Nature 2004;427:695.
7. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
8. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11: 743-50.
9. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
10. Brin MF, Hallett M, Jankovic J. Scientific and therapeutic aspects of Botulinum toxin. New York (USA): Lippincott Williams and Wilkins: 2002. p. 507.
11. Morris JL, Jobling P, Gibbins IL. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001;281:H2124-32.
12. Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002;283:H2627-35.
13. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005;10:92-103.
14. Gallez B, Jordan B, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in tumors. Evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42:627-30.
15. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 2004;17: 240-62.
16. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis 1985;3: 281-94.
17. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143-8.
18. Jordan BF, Grégoire V, Demeure RJ, et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62: 3555-61.
19. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004;49:3389-411.
20. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21: 2831-42.
21. Rogers DF, Boschetto P, Barnes PJ. Plasma exudation. Correlation between Evans blue dye and radiolabeled albumine in guinea pig airways in vivo. J Pharmacol Methods 1989;21:309-15.
22. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal Biochem 1976; 72:248-54.
23. Graff BA, Bjornaes I, Rofstad EK. Macromolecule uptake in human melanoma xenografts: relationships to blood supply, vascular density, microvessel permeability and extracellular volume fraction. Eur J Cancer 2000;36:1433-40.
24. Morris JL, Jobling P, Gibbins IL. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 2002;283:H2627-35.
25. Whall CW, Jr., Havlik RJ, Halpern W, Bohr DF. Potassium depolarization of adrenergic varicosities in resistance arteries from SHR and WKY rats. Blood Vessels 1983;20:23-33.
26. Sonveaux P, Dessy C, Martinive P, et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004;64:3209-14.
27. Sonveaux P, Dessy C, Brouet A, et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radio-sensitization and promotes gene delivery. FASEB J 2002;16: 1979-81.
28. 125I-botulinum- free neurotoxin: time course of tissue distribution. Toxicon 2003;42:461-9.
29. Hsu TSJ, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of Botulinum exotoxin A. Arch Dermatol 2004;140:1351-4.
30. Jordan BF, Sonveaux P, Feron O, et al. Nitric oxide as a radiosensitizer: evidence for an intrinsic role in addition to its oxygen effect on oxygen delivery and consumption. Int J Cancer 2004;109:768-73.
31. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003;29:549-56.